Distant recurrences limit the survival of patients with thalamic high-grade gliomas after successful resection
- PMID: 27987035
- DOI: 10.1007/s10143-016-0804-x
Distant recurrences limit the survival of patients with thalamic high-grade gliomas after successful resection
Abstract
The indications of surgery for thalamic high-grade gliomas are not well established. The present study investigated the outcome of 21 patients treated by surgery and reports the high incidence of distant recurrences including disseminations after successful removal. Twenty-one patients with thalamic high-grade gliomas not invading the pyramidal tract or midbrain underwent cytoreductive surgery at our institute from June 1997 to August 2015. Surgery was performed with the aid of a neuronavigation system, electrophysiological monitoring, and fluorescence navigation. Tumor histology included 12 cases of the World Health Organization grade III and nine cases of grade IV. Gross total resection was achieved in six cases, subtotal in 13, and partial in two. Motor weakness accompanied by sensory disturbance deteriorated immediately after surgery in 13 patients. However, five patients were determined to show deterioration at 2 months after surgery. Postoperative radiation and chemotherapy were given to every patient, and median progression-free survival of patients with grade III and IV tumors was 12.1 and 7.0 months, respectively. Median overall survival of patients with grade III and IV tumors was 25.6 and 12.6 months, respectively. High incidence of distant recurrences was found, with distant lesions at recurrence in 13 of 19 patients with recurrence, suggesting the life-restricting factor in these patients. Thalamic high-grade glioma without invasion into the pyramidal tract and brainstem can be considered as a candidate for surgical resection. Distant lesion limits the survival of patients after successful resection.
Keywords: Dissemination; High-grade glioma; Morbidity; Surgery; Thalamic glioma.
Similar articles
-
Surgical management of thalamic gliomas: case selection, technical considerations, and review of literature.Neurosurg Rev. 2013 Jul;36(3):383-93. doi: 10.1007/s10143-013-0452-3. Epub 2013 Jan 25. Neurosurg Rev. 2013. PMID: 23354786
-
Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas.Neurosurg Focus. 2015 Jan;38(1):E4. doi: 10.3171/2014.10.FOCUS14597. Neurosurg Focus. 2015. PMID: 25552284
-
Role of Intraoperative Neurophysiologic Monitoring in the Resection of Thalamic Astrocytomas.World Neurosurg. 2016 Oct;94:50-56. doi: 10.1016/j.wneu.2016.06.049. Epub 2016 Jun 23. World Neurosurg. 2016. PMID: 27338215
-
Surgical treatment for glioma: extent of resection applying functional neurosurgery.Neurol Med Chir (Tokyo). 2010;50(9):720-6. doi: 10.2176/nmc.50.720. Neurol Med Chir (Tokyo). 2010. PMID: 20885106 Review.
-
Maximizing safe resection of low- and high-grade glioma.J Neurooncol. 2016 Nov;130(2):269-282. doi: 10.1007/s11060-016-2110-4. Epub 2016 May 12. J Neurooncol. 2016. PMID: 27174197 Review.
Cited by
-
H3K27M and TERT promoter mutations are poor prognostic factors in surgical cases of adult thalamic high-grade glioma.Neurooncol Adv. 2021 Feb 28;3(1):vdab038. doi: 10.1093/noajnl/vdab038. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34013205 Free PMC article.
-
The concept of "Four Walls, Two Poles" in the lesions of the thalamus and ganglion regions: case report and literature review.BMC Surg. 2021 Jan 22;21(1):55. doi: 10.1186/s12893-021-01059-9. BMC Surg. 2021. PMID: 33482777 Free PMC article. Review.
-
High-Grade Thalamic Glioma: Case Report with Literature Review.Medicina (Kaunas). 2024 Oct 11;60(10):1667. doi: 10.3390/medicina60101667. Medicina (Kaunas). 2024. PMID: 39459454 Free PMC article. Review.
-
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas.Front Oncol. 2020 Jan 21;9:1568. doi: 10.3389/fonc.2019.01568. eCollection 2019. Front Oncol. 2020. PMID: 32039031 Free PMC article.
-
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):290-295. doi: 10.2176/nmc.ra.2018-0044. Epub 2018 May 31. Neurol Med Chir (Tokyo). 2018. PMID: 29848907 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical